It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What a ...

Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutationsSEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a strategic collaboration with AstraZeneca, a leading pharmaceutical company, to develop AI-powered digital pathology solutions.The solution in focus is Lunit SCOPE Genotype Predictor, an AI-powered to ...

AstraZeneca just released some encouraging data about its weight loss drug candidates. Medications used to treat diabetes and obesity are the hottest commodities in healthcare right now. Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have all become blockbuster drugs, and their momentum doesn't seem to be going away. While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies are looking to enter the space. Earlier thi ...

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

The office building of biopharmaceutical company AstraZeneca is being seen in Shanghai, China, on May 23, 2024. A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox. Subscribe here to receive future editions. AstraZeneca said it is doubling down on its investment in its U.S. business, a move that comes just one week after Donald Trump's election win. AstraZeneca announced plans for $2 billion in new spending on research ...

AstraZeneca's (AZN) third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.01 per share. Core earnings of $2.08 per share fell 20% year over year on a reported basis and 27% at constant exchange rates (CER). Total revenues of $13.57 billion rose 18% on a reported basis and 21% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $13.04 billion. All growth rates ...

9M and Q3 2024 Results Conference call and webcast for investors and analysts 12 November 2024 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, stateme ...

Financial Data and Key Metrics Changes - Total revenue grew by 21% in Q3 2024 and 19% year-to-date, with core EPS increasing by 27% to $2.08 in Q3 and 11% year-to-date [11][12][30] - Alliance revenue increased by 50% to $1.5 billion, driven by sales for Enhertu and Tezspire [23] - Net cash inflow from operating activities improved by $989 million in the first nine months [28] - Net debt increased by $3.8 billion, with a net debt-to-EBITDA ratio of 1.8 times [29] Business Line Data and Key Metrics Changes - Oncology total revenues grew 22% to $16 billion in the first nine months, with Tagrisso global revenues growing 17% [33][34] - BioPharmaceuticals delivered total revenue of $15.9 billion in the first nine months, representing growth of 20% [56] - Rare disease revenue grew 14% to $6.4 billion, with Ultomiris achieving a blockbuster quarter with 35% growth [72] Market Data and Key Metrics Changes - Emerging markets outside of China grew by 30% year-to-date, now accounting for 14% of total revenue [14] - The U.S. market contributed 43% of total revenue, with Europe at 21% and China at 13% [14] Company Strategy and Development Direction - The company announced a $3.5 billion investment in the U.S. for manufacturing and R&D, aiming to increase its market share in the U.S. [15][84] - The company is focused on expanding its oncology portfolio and has multiple high-value Phase 3 readouts expected [19][76] - The long-term goal is to achieve $80 billion in total revenue by 2030, with a mid-30s percentage operating margin by 2026 [78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high-teens percentage growth for total revenue and core EPS for the full year [30] - The company acknowledged potential headwinds from the IRA and VBP in China but remains optimistic about overall growth momentum [86] - Management emphasized the importance of innovation and the U.S. market's role in supporting future growth [84] Other Important Information - The company is committed to its presence in China and continues to invest in R&D despite ongoing investigations [17][18] - The company is advancing its pipeline with several new medicines and indication expansions expected to drive future growth [76] Q&A Session Summary Question: U.S. election implications and investment focus - Management indicated that pharmaceuticals are typically not subject to import duties and emphasized the importance of the U.S. market for innovation and growth [81][83] Question: Confidence in the 2025 outlook - Management expressed confidence in achieving growth despite potential headwinds, citing strong momentum across the portfolio [85][86] Question: Materiality of impact from the investigation in China - Management stated it is too early to judge the impact but acknowledged that growth in China may slow next year [92][93] Question: Confidence in Dato-DXd and FDA review - Management highlighted ongoing discussions with the FDA regarding subgroup analyses and expressed confidence in the potential of Dato-DXd based on recent data [95][100]

Astrazeneca (AZN) reported $13.57 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 18%. EPS of $1.04 for the same period compares to $0.87 a year ago.The reported revenue represents a surprise of +4.02% over the Zacks Consensus Estimate of $13.04 billion. With the consensus EPS estimate being $1.01, the EPS surprise was +2.97%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Company Performance - AstraZeneca increased its full-year sales outlook due to booming demand for its cancer and rare-disease drugs [1][2] - The company now projects fiscal 2024 revenue and core EPS to grow by a high-teens percentage, up from a mid-teens percentage [2] - AstraZeneca reported higher-than-estimated Q3 results with revenue of $13.57 billion, up from $11.49 billion last year, and core EPS of $2.08, beating estimates of $2.06 [4] Investment Plans - AstraZeneca plans to invest $3.5 billion in its U.S. business by the end of 2026, including $2 billion to create more than a thousand new high-skilled jobs [1][3] - The investment will expand the company's U.S. research and manufacturing footprint, including an R&D center in Cambridge, Mass., a biologics manufacturing facility in Maryland, specialty manufacturing in Texas, and cell therapy manufacturing capacity on the West and East Coasts [3] Market and Demand - The company's strong growth trajectory in the first nine months of 2024 reflects growing demand for medicines across oncology, biopharmaceuticals, and rare disease [3] Legal and Regulatory - AstraZeneca has not received any notification that it is under investigation in China despite senior executives being implicated in an insurance fraud case [5]